Table 5.

Univariate Cox regression analysis of post-RP BCF using 32-gene risk index scores from needle biopsy tissue samples

Variable	HR (95% CI)	P value
32-Gene risk index	4.92 (1.45–16.78)	0.0107
Gleason score at biopsy		0.0162
7 vs. ≤6	3.21 (2.96–3.48)	0.0052
≥8 vs. ≤6	2.80 (0.78–10.06)	0.1155
cT stage (2 vs. 1)	0.83 (0.25–2.76)	0.7638
Proportion of cores positive (>⅓ vs. ≤⅓)	1.03 (0.48–2.23)	0.9306
Highest percent positive core	1.00 (0.88–1.13)	0.9955
Log(1+baseline PSA)	2.09 (1.19–3.65)	0.0098

Validation cohort, n = 79.

The HR calculated for the 32-gene index is based on a five-unit change. All variables are pre-RP values.